キャンディン新薬の考察と市場予測（2032年）

当レポートでは、キャンディン新薬の主要7市場（米国・ドイツ・フランス・イタリア・スペイン・英国・日本）について調査分析し、作用機序、用法と用量、研究開発活動についての考察、市場予測などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 尋常性疣贅（いぼ）におけるキャンディンの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 治験情報
  • 安全性と有効性
• 規制のマイルストーン
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（後期の新しい治療法）

第4章 キャンディン市場の評価

• 尋常性疣贅（いぼ）におけるキャンディンの市場の見通し
• 主要7市場の分析
  • 主要7市場の尋常性疣贅（いぼ）向けキャンディンの市場規模
• 市場の分析：国別
  • 米国の尋常性疣贅（いぼ）向けキャンディンの市場規模
  • ドイツの尋常性疣贅（いぼ）向けキャンディンの市場規模
  • 英国の尋常性疣贅（いぼ）向けキャンディンの市場規模

第5章 SWOT分析

第6章 アナリストの見解

第7章 付録

第8章 DelveInsightのサービス内容

第9章 免責事項

第10章 DelveInsightについて

第11章 レポート購入オプション

List of Tables

• Table 1: CANDIN, Clinical Trial Description, 2023
• Table 2: CANDIN, General Description
• Table 3: Competitive Landscape (Emerging Therapies)
• Table 4: CANDIN Market Size in the 7MM, in USD million (2019-2032)
• Table 5: CANDIN Market Size in the US, in USD million (2019-2032)
• Table 6: CANDIN Market Size in Germany, in USD million (2019-2032)
• Table 7: CANDIN Market Size in France, in USD million (2019-2032)
• Table 8: CANDIN Market Size in Italy, in USD million (2019-2032)
• Table 9: CANDIN Market Size in Spain, in USD million (2019-2032)
• Table 10: CANDIN Market Size in the UK, in USD million (2019-2032)
• Table 11: CANDIN Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: CANDIN Market Size in the 7MM, USD million (2019-2032)
• Figure 2: CANDIN Market Size in the United States, USD million (2019-2032)
• Figure 3: CANDIN Market Size in Germany, USD million (2019-2032)
• Figure 4: CANDIN Market Size in France, USD million (2019-2032)
• Figure 5: CANDIN Market Size in Italy, USD million (2019-2032)
• Figure 6: CANDIN Market Size in Spain, USD million (2019-2032)
• Figure 7: CANDIN Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: CANDIN Market Size in Japan, USD million (2019-2032)

"CANDIN Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about CANDIN for Common Warts in the seven major markets. A detailed picture of the CANDIN for Common Warts in the 7MM, i.e., the United States, EU4 (Germany, France, Italy and Spain) and the United Kingdom, and Japan for the study period 2019-2032 is provided in this report along with a detailed description of the CANDIN for Common Warts. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the CANDIN market forecast, analysis for Common Warts in the 7MM descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Common Warts.

Drug Summary:

CANDIN is a clear, colorless, sterile solution with a pH of 8.0-8.5. It is made from the culture filtrate and cells of two strains of Candida albicans. The fungi are propagated in a chemically defined medium consisting of inorganic salts, biotin, and sucrose.

Cellular hypersensitivity, or delayed-type hypersensitivity (DTH), can be assessed by intracutaneous testing with bacterial, viral, and fungal antigens to which most healthy persons are sensitized.

The active ingredient in CANDIN, currently approved as a skin test antigen for the assessment of cellular hypersensitivity to Candida albicans, is currently under investigation for the treatment of verruca vulgaris or common warts. The antigen in CANDIN is not currently approved for the treatment of common warts or any other indications.

Results in Phase II research involving common and non-common warts among adults were highly encouraging and are now advancing clinical research into the use of the antigen in common and non-common warts. Though not treated, plantar, periungual, flat, facial, and genital warts were evaluated in the Phase II subjects. Nielsen BioSciences has completed a Phase II clinical trial and is currently planning for a pivotal Phase III study for this indication.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the CANDIN description, mechanism of action, dosage and administration, research and development activities in Common Warts.
• Elaborated details on CANDIN regulatory milestones and other development activities have been provided in this report.
• The report also highlights the CANDIN research and development activity in Common Warts in detail across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around CANDIN.
• The report contains forecasted sales of CANDIN for Common Warts till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Common Warts.
• The report also features the SWOT analysis with analyst views for CANDIN in Common Warts.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

CANDIN Analytical Perspective by DelveInsight

• In-depth CANDIN Market Assessment

This report provides a detailed market assessment of CANDIN in Common Warts in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

• CANDIN Clinical Assessment

The report provides the clinical trials information of CANDIN in Common Warts covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Common Warts is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence CANDIN dominance.
• Other emerging products for Common Warts are expected to give tough market competition to CANDIN and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of CANDIN in Common Warts.
• Our in-depth analysis of the forecasted sales data from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the CANDIN in Common Warts.  

Key Questions

• What is the product type, route of administration and mechanism of action of CANDIN?
• What is the clinical trial status of the study related to CANDIN in Common Warts and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the CANDIN development?
• What are the key designations that have been granted to CANDIN for Common Warts?
• What is the forecasted market scenario of CANDIN for Common Warts?
• What are the forecasted sales of CANDIN in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available in Common Warts and how are they giving competition to CANDIN for Common Warts?

Which are the late-stage emerging therapies under development for the treatment of Common Warts?

Table of Contents

1. Report Introduction

2. CANDIN Overview in Common Warts

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory milestones
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Late-stage Emerging Therapies)

4. CANDIN Market Assessment

• 4.1. Market Outlook of CANDIN in Common Warts
• 4.2. 7MM Analysis
  • 4.2.1. Market size of CANDIN in the 7MM for Common Warts
• 4.3. Country-wise Market Analysis
  • 4.3.1. Market size of CANDIN in the United States for Common Warts
  • 4.3.2. Market size of CANDIN in Germany for Common Warts
  • 4.3.3. Market size of CANDIN in France for Common Warts
  • 4.3.4. Market size of CANDIN in Italy for Common Warts
  • 4.3.5. Market size of CANDIN in Spain for Common Warts
  • 4.3.6. Market size of CANDIN in the United Kingdom for Common Warts
  • 4.3.7. Market size of CANDIN in Japan for Common Warts

5. SWOT Analysis

6. Analysts' Views

7. Appendix

• 7.1. Bibliography
• 7.2. Report Methodology

8. DelveInsight Capabilities

9. Disclaimer

10. About DelveInsight

11. Report Purchase Options